trial · primary record
Ceramide NanoLiposome (Ceraxa)
Acute Myeloid Leukemia, in Relapse
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 15 |
| Primary completion | 2027-02-28 |
| Primary endpoint | Number of Patients with Dose Limiting Toxicities as defined in Protocol Section 13.5 |
| Registry ID | NCT04716452 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:31.062Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04716452
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.